Prediction of hepatic metabolic clearance -: Comparison and assessment of prediction models

被引:68
作者
Zuegge, J [1 ]
Schneider, G [1 ]
Coassolo, P [1 ]
Lavé, T [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Div Pharmaceut, Preclin Pharmacokinet, CH-4070 Basel, Switzerland
关键词
D O I
10.2165/00003088-200140070-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To perform a comparative quantitative evaluation of the prediction accuracy for human hepatic metabolic clearance of 5 different mathematical models: allometric scaling (multiple species and rat only), physiologically based direct scaling, empirical in vitro-in vivo correlation, and supervised artificial neural networks. Methods: The mathematical prediction models were implemented with a publicly available dataset of 22 extensively metabolised compounds and compared for their prediction accuracy using 3 quality indicators: prediction error sum of squares (PRESS), r(2) and the fold-error. Results: Approaches such as physiologically based direct scaling, empirical in vitro-in vivo correlation and artificial neural networks. which are based on in vitro data only, yielded an average fold-error ranging from 1.64 to 2.03 and r(2) values greater than 0.77, as opposed to r(2) values smaller than 0.44 when using allometric scaling combining in vivo and in vitro preclinical data. The percentage of successful predictions (less than 2-fold error) ranged from 55% (rat allometric scaling) to between 64 and 68% with the other approaches. Conclusions: On the basis of a diverse set of 22 metabolised drug molecules, these studies showed that the most cost-effective and accurate approaches, such as physiologically based direct scaling and empirical in vitro-in vivo correlation, are based on in vitro data alone. Inclusion of in vivo preclinical data did not significantly improve prediction accuracy; the prediction accuracy of the allometric approaches was at the lower end of all methods compared.
引用
收藏
页码:553 / 563
页数:11
相关论文
共 42 条
[1]   PLS regression methods [J].
Höskuldsson, Agnar .
Journal of Chemometrics, 1988, 2 (03) :211-228
[2]   Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man [J].
Bayliss, MK ;
Bell, JA ;
Jenner, WN ;
Park, GR ;
Wilson, K .
XENOBIOTICA, 1999, 29 (03) :253-268
[3]  
Bishop C. M, 1995, NEURAL NETWORKS PATT
[4]   SCALING OF ANTIPYRINE INTRINSIC CLEARANCE OF UNBOUND DRUG IN 15 MAMMALIAN-SPECIES [J].
BOXENBAUM, H ;
FERTIG, JB .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1984, 9 (02) :177-183
[5]   FIRST-TIME-IN-HUMAN DOSE SELECTION - ALLOMETRIC THOUGHTS AND PERSPECTIVES [J].
BOXENBAUM, H ;
DILEA, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10) :957-966
[6]   INTERSPECIES PHARMACOKINETIC SCALING AND THE EVOLUTIONARY-COMPARATIVE PARADIGM [J].
BOXENBAUM, H .
DRUG METABOLISM REVIEWS, 1984, 15 (5-6) :1071-1121
[7]  
Brown P. J., 1993, MEASUREMENT REGRESSI
[8]  
Campbell DB., 1994, DRUG INF J, V28, P235, DOI DOI 10.1177/009286159402800130
[9]   A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development [J].
Cross, DM ;
Bayliss, MK .
DRUG METABOLISM REVIEWS, 2000, 32 (02) :219-240
[10]   THE BACKPROPAGATION NEURAL-NETWORK - A BAYESIAN CLASSIFIER - INTRODUCTION AND APPLICABILITY TO PHARMACOKINETICS [J].
ERB, RJ .
CLINICAL PHARMACOKINETICS, 1995, 29 (02) :69-79